Movement Alert|Liquidia Technologies Rises 15.51% in Regular Trading, Trading at $63.95

Market Focus
06/04

On June 4, Liquidia Technologies rose 15.51% in regular trading, trading at $63.95 USD/share, with trading volume of $112 million.

Within the Pharmacy sector where Liquidia Technologies belongs, individual stocks showed broad gains. Among them, Eli Lilly up 5.16%, Johnson & Johnson up 1.44%, Novo-Nordisk up 5.17%, Merck up 3.04%, Pfizer up 1.32%.

Liquidia Corporation is a biopharmaceutical company focused on the development, manufacturing, and commercialization of products for unmet patient needs, with current emphasis on pulmonary arterial hypertension treatment. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil, and Remodulin. The company leverages its proprietary PRINT particle engineering technology platform to precisely produce uniform drug particles for improved therapeutic performance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10